A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Titel:
A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Auteur:
Daver, Naval Assi, Rita Ravandi, Farhad Garcia-Manero, Guillermo Jabbour, Elias DiNardo, Courtney D. Kadia, Tapan M. Ning, Jing Nogueras-Gonzalez, Graciela Pierce, Sherry Gombos, Dan Kornblau, Steven Konopleva, Marina Kelly, Mary Borthakur, Gautam Zhang, Weiguo Cortes, Jorge Kantarjian, Hagop Andreeff, Michael